News

Symphogen Presents Positive Rozrolimupab (SYM001) Phase 2 Trial Results in ITP at ASH

Symphogen Announces Initiation of Phase 2 Trial of Sym004 EGFR Antibody Mixture in Patients with Squamous Cell Carcinoma of Head and Neck Cancer

Symphogen Presents Preliminary Results from Phase 2 Clinical Trial with Rozrolimupab at the Annual European Hematology Association

Calendar

	The Immunotherapeutics Partnering and Dealmaking Conference
	Speaker: Gayle Mills, Chief Business Officer

• January 30 - 31, 2012 San Diego, CA, USA

	Protein Therapeutics Forum 2012
	Speaker: Dr. Ivan D. Horak, Chief Scientific and Medical Officer

• January 30 - February 1, 2012 Washington DC

	Cell Culture 2012
	Speaker: Christian Müller, PhD, Senior Scientist

• February 2 2012 - February 3 2013 San Diego, USA

	Informa Life Sciences, Cell Line Development & Engineering Conference
	Speaker: Christina Andersen, Scientist

• February 13 - 17, 2012 The Radisson Blu Hotel, Cologne, Germany

Shortcuts